The growing interest in minimal residual disease (MRD)assessment in multiple myeloma (MM) is related to thehigh quality of responses achieved with novel agents andto the development of reliable techniques to evaluateMRD both within the bone marrow using next-generationsequencing (NGS) or next-generationflow cytometry(NGF), and outside the bone marrow using imagingtechniques, such as positron emission tomography-computed tomography (PET-CT)1. A consensus paperby the International Myeloma Working Group (IMWG),published in 2016, represents the reference document onMRD in MM2.
No takes yet. Share an insight, caveat, or question.
Moreau et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: